team to and you, Bausch part Thank lies of the excited the leadership that journey for ahead Tom. be I'm the Health company.
and consolidated Lomb. performance, segment let Bausch our additional share Bausch we Before + review me performance of QX excluding headlines our Health, at results some
is Revenue adjusted the cash of our continued and generated As Even outflows. demonstrating EBITDA. of growth X% associated adjusted year the the ago. timing certain benefit of versus EBITDA more expectations and million portfolio increase was this when was of diversified which in consecutive businesses. quarter sixth well X%, from of both period adjusted Tom even year-over-year we a same revenue adjusted ahead noted, of flow for growth operating and our XX% quarter grew $XXX This operations, a importantly, for is leverage with
More bit months performance translated cash and raising flow. revenue little year into adjusted our later. specific adjusted strong has full last Our the that on a EBITDA over for now X operating guidance
was Adjusted our Revenue basis prior find non-GAAP billion, same to now consolidated X. than on which the margin a for ago. year. you year XX% the financial higher $X.XX XX period the up gross versus Page Moving quarter, results points will was XX.X%, third
XX% same quarter a Health, For a to the and, compared third Bausch margin margin lesser when to compared of + points XXX pricing + approximately was the for Bausch mix. higher product gross gross adjusted adjusted ago, the At XX% and for thanks quarter XXXX. to favorable quarter was XX.X%, to net the extent, third Bausch excluding Lomb, third year period for basis channel Lomb,
were driven of adjusted the third $XXX from improvement impact mix, increase the same of an This primarily year. the product including Consolidated million, last million by $XXX expenses operating period was quarter Xiidra. for
and A&P and $XX Xiidra last behind adjusted by which Mybel due of adjusted quarter expenses For to increased reported million compared the or revenue $XXX quarter primarily of million of was year. Lomb, X% QX was million Bausch by X.X% driven R&D expenses of ]. selling compared Bausch a operating Consolidated decrease Health, Bausch XXXX. adjusted investment [ for to third the of an to $XXX increased increase expense + excluding operating Lomb + in
last than primarily lower R&D Bausch Health, B&L, million planned of were expenses timing approximately million third spend. excluding quarter $XX year's driven For of $XX by
Health, adjusted year. same X% million quarter EBITDA was to attributable of or XX% Health EBITDA Bausch Lomb, million, quarter Third $XX XXXX. to Adjusted consolidated $XXX for as the last Bausch Bausch of excluding million a quarter $XXX an the from third compared + increase was increase
On cash generated consolidated cash of a adjusted cash basis, $XXX and Turning flow. to in Basel million of flow million QX. now flow operating $XX operating
$XXX excluding For Bausch million + operating was the strength of performance exceptional to $XXX million, up compared Bausch of when adjusted our results operating Health, Lomb, of third across XXXX. quarter all This cash the reflects segments. flow
of starting by increase the $XX with third growth business The year-over-year. Page in or now performance quarter X% on Salix our XX. to segment, revenues million were million, $XXX Salix Moving an our
Our new setting Total X% with existing least revenue X demand X%. growth which saw at of and patients scripts no as grew grew Relistor such in new ] growth. The drive patients. as underlying and XIFAXAN, X%. for includes and outpatient all units well major double-digit ] most by script retail continues TRULANCE at Extend the hospital as salmon X% to grew XIFAXAN bolstered strong brands, growth [ namely Salix clinics, [ and
strong, inventory net was demand pricing compared were to in by channel impacted revenue last Although year. reduction partly dynamics wholesaler and XIFAXAN XX% a
the during and compared on X% third the EMEA quarter, basis Page to XX. Revenues segment reported Lat and the to basis on between brand, balanced In $XXX local to volume all saw the was revenue ] by International during quarter. was private In of growth growth an flagship as thanks opportunistic our and channel, America, Am organic X% last double brands such grew an Now of [ promoted particularly increase moving fueled our Latin were Contrave digit, Bedoyecta. a quarter and Ryaltris of our our year. our Canada, organic Wellbutrin. on Canada, million which some
in Solta a Revenues during to QX. terrific revenue Medical Now the increase primary moving of to represents and of quarter on to quarter, Solta's our South Pacific reported basis. China, segment, XX% review of with about which growth the XX a Taiwan. third had were Page $XXX performance XX% particular million region, Korea be which continues in engine The Salter strong Asia global an contributor
second China, exceeded for the during market Thermage has expectations. as outstanding the of and broadening as new channels, our then, quarter relaunch such coverage produced relevance In Korea, South Since is our medical results. device our FLX market In performance expansion clinics has a hospitals.
We on track XXXX to in Korean our more XX% are compared now growing by business for XXXX. when than
ago. compared a to the during of $XXX you period the and quarter, which third our basis Page will an X% performance same increase find Turning year segments, on million reported were our focus on a diversified XX. the now X% of basis an on to organic Revenues
supply and an of suppliers. advantage capabilities supply primarily driven In we allow our were XX% Separately, grew, in cards generic expecting. Canada Wellbutrin order XX%. like to did of in us manufacturing not $XX the of was we quarter business, chain our take Aplenzin, and Wellbutrin, as for neurology and million which Growth thanks to by we flexible recorded respectively, shortages highly QX,
that the to Finally, Revenues businesses an results, basis geographies. period by across quarter, balanced by XX. billion and basis let the XX% wrap performance segment are Page to same on Important all + and up line top third reported year. XX% well on $X.X Bausch was the during the compared summarizing up me a on were last note Lomb growth organic which
Turning our balance to now sheet.
Tom focusing earlier, prioritize while reduce liquidity our alternatives also continue overall maturities evaluate to debt upcoming As we to and obligation. our indicated leverage management on
we $XXX for value of million net year-to-date of capturing settlements XXXX the million, and cash a see by basis, On As $XXX debt Bausch $XXX XXXX reduction our legal you net quarter, third Health, in will in on payments Bausch debt, excluding principal + including to Page for maturities, reduced XX, approximately discount. the our legacy Lomb million. impact amounts approximately of
and our many million We up a amortization portion AR $XX repaid performance, also towards excellent was quarterly which loan our on rounds fronts. term mandatory facility. This under
our year will guidance excluding Bausch Let's B&L, find which you Health, on now move to for full XX. Page
our follows. of in be the earlier, our in outlook. the $XX revenue have guidance. increased X%, the with to profit year up full XXXX, strength prior now points to to guidance our and line between guidance and with expect go, over As flow just billion XXX previous by stands revenue X% indicated of our Separately, has of billion, and growth X X cash to million. quarter our guidance as first months million performance allowed We us range we by $X.XXX approximately narrowed to $X.XX increase when the basis compared midpoint Organic range of now the $XX
points adjusted XXX We are guidance. basis for gross up our approximately increasing also our prior XX%, guidance to from margin
$X.XXX port. an increase billion $XX range the at also between mid to million For our while $X.XXX our and of adjusted guidance increasing are EBITDA, we narrowing billion,
from XX. adjusted billion, guidance. of million to an our operations, guidance progress between front well $XXX on outlined in on creation cash QX we we prior as increase and we are about Page increasing framework, made flow $X.XXX Finally, have a The our several million $XXX our illustrates range value how think versus
vectors. Our X focus divided is among equally
our include which innovation as Health across continuing increasing growth assets, the portfolio to globe. operational brands of value the wide Bausch as optimize the First, of of well
leverage our all for options which maturities. includes but least, of reducing Health equity And capital our Bausch structure, maximizing not extending evaluating our value for Second, B&L's debt and shareholders. the third, optimizing stake
concluded, will so our or to project on these the process hand our to will represents vectors now up. I creation future. is any X wrap be today specific value to the back policy not While focus primary yet continue of and for Tom comment not it foreseeable it in
